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tardiac resynchronization therapy (CRT) is a promising
ew approach for improving outcomes among patients who
ave heart failure, reduced left ventricular (LV) systolic
unction, and a wide QRS complex. Cardiac resynchroni-
ation therapy devices are quite expensive, however, so their
ost effectiveness is of concern now that the costs of health
are are increasing rapidly once again. Randomized clinical
rials can provide unbiased measures of the economic
utcomes of new therapies, just as they do for clinical
utcomes. However, the short-term results of trials do not
rovide a complete picture of health and economic out-
omes, especially for devices and procedures. Consequently,
any investigators now use a model to extrapolate trial
esults and analyze cost effectiveness (1). In this issue of the
ournal, this approach has been taken to evaluate the
conomic outcomes of the Comparison of Medical Ther-
py, Pacing, and Defibrillation in Heart Failure (COM-
ANION) trial (2).
See page 2311
The COMPANION trial randomized patients to either
RT with implantable cardioverter-defibrillator (ICD) ca-
ability, CRT without ICD capability, or optimal medical
herapy (3). The COMPANION trial found that CRT,
ither with or without ICD capability, significantly im-
roved patient functional status and quality of life compared
ith optimal medical therapy. The COMPANION trial
lso found that the combined CRT-ICD device, but not
RT alone, reduced mortality significantly compared with
edical therapy. The COMPANION investigators now
eport that the costs of CRT alone and of combined
RT-ICD therapy are substantially higher than the cost of
edical therapy (2). Because the observed follow-up in the
OMPANION trial was much too brief to give a fair
icture of the cost effectiveness of these devices, the inves-
igators used a model to extrapolate their results to seven
ears, and suggest that CRT therapy is cost effective. Before
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.(
From the Department of Health Research and Policy and the Department of
edicine, Stanford University School of Medicine, Stanford, California.ccepting this conclusion, it is important to examine how
heir results were achieved and consider the relevance of
hese findings to current clinical decision-making.
RINCIPLES OF COST EFFECTIVENESS
ost-effectiveness analysis is an analytic tool that organizes
nformation about medical interventions and facilitates
udgments about whether a therapy improves outcomes
ufficiently to justify the added cost. One of the key
rinciples of cost-effectiveness analysis is that a new therapy
hould be compared with the next best alternative therapy.
he costs and benefits of the new therapy compared with
he best alternative are used to calculate the incremental
ost-effectiveness ratio:
CE
CostCRTCostMED
Life YearsCRTLife YearsMED
Cost-effectiveness ratios of $50,000 per life-year added
re generally considered acceptable in the U.S., whereas
alues $100,000 are generally considered too expensive,
nd the middle range of $50,000 to $100,000 is a “gray
one.”
OSTS
he net cost of any device includes more than the price of
he hardware and the cost of implantation. Device compli-
ations will increase the net cost, whereas prevention of
isease complications by the device may reduce the net cost.
he COMPANION investigators estimated the initial
mplantation costs to be $20,500 for CRT alone and
29,500 for the combined CRT-ICD device (2). They
rojected that post-implantation costs over the next seven
ears would be $39,400 in the CRT-alone group and
52,700 in the CRT-ICD group, compared with $46,000 in
he medical therapy group. Thus, the long-term cost of the
ombined CRT-ICD device ($82,200) was much higher
han the cost of CRT alone ($59,900) or of medical therapy
$46,000).
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lthough CRT therapy is costly, the increased cost may be
cceptable if outcomes are sufficiently improved. A therapy
s considered effective if it either increases life expectancy or
mproves quality of life, or both. The length and quality
f life can be combined as quality-adjusted life-years
QALYs), a measure of effectiveness that underscores that
mproving either outcome is desirable.
The evidence from several clinical trials shows that CRT
ignificantly improves quality of life for the average patient
ligible for randomization (4). The degree of improvement
n quality of life is clinically meaningful and certainly
ontributes to the overall effectiveness of CRT. The effect of
RT alone on mortality has been uncertain, but the recently
ublished Cardiac Resynchronization Heart Failure
CARE-HF) trial showed CRT reduced mortality signifi-
antly compared with medical therapy (5). The weight of
vidence now suggests that CRT devices without ICD
apability reduce mortality and improve quality of life in
atients with heart failure.
The combined CRT-ICD device in the COMPANION
rial reduced mortality and improved quality of life significantly
ompared with medical therapy (3). The COMPANION trial
id not formally compare the combined CRT-ICDwith CRT
lone, but the small differences in mortality and quality of
ife between these devices are almost certainly not statisti-
ally significant (3). The data from the COMPANION trial
uggest that CRT therapy in patients with heart failure
ields better outcomes than medical therapy, but that
either device is clearly superior to the other.
OST EFFECTIVENESS
he CRT device alone in the COMPANION trial was
uch less expensive than the combined CRT-ICD device
nd had very similar clinical outcomes. A prudent buyer
ould first look at the less expensive CRT-alone device, and
hen ask whether the combined CRT-ICD device is worth
he considerable added expense. A formal cost-effectiveness
nalysis similarly first compares CRT alone with medical
herapy, and then compares the combined CRT-ICD
evice with the next best alternative, which is CRT alone.
Compared with optimal medical therapy, CRT alone in
he COMPANION trial had a cost-effectiveness ratio of
19,600 per QALY added, which is well within the range of
ther generally accepted interventions. The overall benefit
f 0.71 QALYs resulted from the significant improvement
n quality of life and the trend toward improved survival.
he COMPANION trial therefore provides direct evidence
hat CRT without ICD capability can be a cost-effective
herapy in properly selected patients with heart failure, low
jection fraction, and a wide QRS.
Does the more costly combined CRT-ICD device im-
rove outcomes sufficiently to be worthwhile? The appro-
riate comparison is against CRT alone, the next best alter-
ative, and not with medical therapy. The COMPANION brial data show that the combined CRT-ICD had only slightly
etter outcomes than CRT alone (3.15 vs. 3.01 QALYs) but
ost much more ($82,200 vs. $59,900). The cost effectiveness
alculated from these data is $160,000 per QALY, which is
xpensive compared with standard benchmarks. The COM-
ANION trial data suggest that adding ICD capability to a
RT device may not improve outcomes sufficiently to justify
he considerable additional expense.
LINICAL CONTEXT
he CRT device aims to improve the efficiency of cardiac
ontraction and thereby ameliorate the underlying physio-
ogic defect in patients with heart failure. Clinical trials of
RT initially assessed the effect of CRT on symptoms and
unctional capacity, and only recently examined whether
RT reduces mortality in patients with heart failure. The
otality of evidence from clinical trials suggests that CRT
lone reduces mortality by roughly 20% compared with
edical therapy.
While CRT was being developed, an independent avenue
f investigation has tested whether prophylactic implanta-
ion of an ICD reduces mortality in patients with a reduced
jection fraction, with or without heart failure. Large trials
uch as Sudden Cardiac Death in Heart Failure Trial
SCD-HeFT) suggest that an ICD alone can reduce mor-
ality by 23% or more (6).
Because the mechanisms of action of CRT and ICD
evices are quite different, it is reasonable to hypothesize
hat they may have an additive effect on mortality. It is
mportant to recognize, however, that the effects of these
evices may not be additive—that the 20% mortality reduc-
ion from CRT may overlap the 23% mortality reduction
rom an ICD. The only way to prove that the combined
RT-ICD device leads to better outcomes than either CRT
lone or ICD alone is to perform head-to-head comparison
rials. The ongoing Multicenter Automatic Defibrillator
mplantation Trial with Cardiac Resynchronization Ther-
py (MADIT CRT) and REsynchronization reVErses Re-
odeling in Systolic left vEntricular dysfunction (RE-
ERSE) trial are comparing ICD alone with combined
RT-ICD therapy; these studies, along with previous trials
7–9), should provide adequate power to test the hypothesis.
y contrast, the combined CRT-ICD device has been
ompared with CRT alone only in the COMPANION
rial, and that single study was not large enough to show a
ifference between these devices in clinical outcomes.
VIDENCE
vidence is accumulating to show that device therapy
mproves outcomes compared with medical therapy in
atients with heart failure. There are clearly differences
mong devices in their capabilities, reliability, and cost. Too
ew head-to-head comparisons have been done among the
arious devices to show clearly whether one has significantly
etter clinical outcomes in this patient population. Al-
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Editorial Comment December 20, 2005:2322–4hough it is seductive to believe that devices with more
eatures should lead to better outcomes than simpler and
heaper devices, recent experience with dual-chamber pac-
ng (10,11) should warn us that this supposition is often
ncorrect. The more complex CRT-ICD devices are signif-
cantly more costly, but there is no solid evidence showing
hat they lead to significantly better outcomes than CRT
lone. Are they really a good value? Only properly sized
omparative clinical trials can answer this question.
Medical technology is a moving target, with constantly
mproving therapies and outcomes. Cost-effectiveness anal-
sis compares the newest therapy with the next best alter-
ative, just as prudent clinicians do. The CRT-alone device
eems to be cost effective compared with medical therapy for
atients with heart failure, reduced ejection fraction, and a
ide QRS. The combined CRT-ICD device has only
arginally better outcomes than CRT alone, at a signifi-
antly higher cost. The question of which device is the most
ost effective for patients with heart failure remains open.
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